Stockwinners Market Radar for October 24, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT Critical Metals to go public on Nasdaq through Sizzle Acquisition combination - European Lithium AT Limited, a wholly owned subsidiary of European Lithium, and Sizzle Acquisition announced that they have entered into a definitive agreement for a business combination that will result in the formation of Critical Metals Corp., which is expected to be a leading lithium mining company. Upon closing, subject to approval by European Lithium and Sizzle stockholders and other customary requirements, Critical Metals intends to be listed on Nasdaq under the symbol "CRML," which is expected to occur in the first half of 2023.

20:04 EDT Cathie Wood's ARK Investment bought 302.3K shares of Prime Medicine today

20:02 EDT Cathie Wood's ARK Investment bought 10.8K shares of Tesla today

19:47 EDT Astellas to buy 15% of Taysha Gene Therapies for $50M, obtain TSHA-102 license - Astellas Pharma (ALPMY) and Taysha Gene Therapies (TSHA) "announced a strategic investment to support the advancement of Taysha's adeno-associated virus gene therapy development programs for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas' global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha's innovative AAV gene therapy development programs for genetic diseases of the central nervous system create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs. Under the terms of the agreement, Astellas will invest a total of $50 million to acquire 15% of the outstanding common stock of Taysha and to receive an exclusive option to license two of Taysha's clinical stage programs: TSHA-102 for Rett syndrome and TSHA-120 for GAN. In addition, Taysha has granted Astellas certain rights related to any potential change of control of Taysha. Definitive agreements would be executed upon Astellas' exercise of any such option, and any change of control transaction would require approval by Taysha's stockholders. Taysha is engaged in the development of intrathecally-delivered AAV gene therapies for monogenic CNS diseases. As a part of this platform approach, Taysha has a promising pipeline, including TSHA-102, which is the first-and-only gene therapy in clinical development for Rett syndrome, and TSHA-120, which is in Phase 1/2 development for the treatment of GAN and awaiting regulatory feedback."

18:20 EDT AudioEye and accessiBe reach global settlement of pending legal disputes - AudioEye and accessiBe announced they have agreed to a global settlement of all pending legal disputes, which includes mutual covenants not to sue, and will move forward with their businesses. The parties and their customers and partners will continue to have full freedom to operate and leverage the full scope of the parties' respective technology moving forward. The parties have also agreed to a framework designed to avoid and manage disputes in the future so they can focus on their respective businesses.

17:40 EDT Vitru receives antitrust approval for investment agreement with Crescera - Vitru Limited "announced that the General Superintendence of CADE has approved, without any restrictions, the investment agreement with Crescera Growth Capital Master V Fundo de Investimento em Participacoes Multiestrategia and Crescera Growth Capital V Coinvestimento III Fundo de Investimento em Participacoes Multiestrategia. CADE's decision will only become final after a period of 15 days from its publication in the Official Gazette of the Union, which occurred today, without any appeals or recall by the CADE Court, under the terms of the applicable legislation."

17:29 EDT Warner Bros. Discovery sees $3.2B-$4.3B in pre-tax restructuring charges - In a regulatory filing, Warner Bros. Discovery said it estimates it will incur $1.3B-$1.6B of pre-tax restructuring charges in Q3. As previously announced, on April 8, 2022, Warner Bros. Discovery Inc. formerly known as Discovery Inc., completed its acquisition of the WarnerMedia business of AT&T Inc. In connection with the completion of the acquisition, management has announced and has taken actions to implement projects to achieve significant cost synergies for the company. As part of its plan to achieve significant cost synergies, in Q3 2022, the company finalized the framework supporting its ongoing restructuring and transformation initiatives which will include, among other things, strategic content programming assessments, organization restructuring, facility consolidation activities and other contract termination costs. The company estimates it will incur approximately $3.2B-$4.3B in pre-tax restructuring charges comprised of: Strategic content programming assessments, leading to content impairment and development write-offs, of approximately $2B-$2.5B; Organization restructuring costs, including severance, retention, relocation, and other related costs: $800M-$1.1B; and facility consolidation activities and other contract termination costs: $400M-$700M. Of the total amounts above, the estimated cash expenditures from the organization restructuring, facility consolidation activities and other contract termination costs will be in the range of approximately $1B-$1.5B. The company incurred $1B of pre-tax restructuring charges in Q2 2022 and estimates $1.3B-$1.6B of additional pre-tax restructurings charges, primarily attributable to content, in Q3 2022. While the company's restructuring efforts are ongoing, including the strategic analysis of content programming which could result in additional impairments above the estimate provided above, the restructuring initiatives are expected to be substantially completed by the end of 2024.

17:26 EDT Crown Castle director buys $150.4K in common stock - In a regulatory filing, Crown Castle disclosed that its director Matthew Thornton bought 1.2K shares of common stock on October 21 in a total transaction size of $150.4K.

17:15 EDT Crown Holdings CEO sees margins under pressure for 'balance of 2022' - Commenting on the quarter, Timothy Donahue, Chairman, President and CEO, stated, "Third quarter global beverage can shipments outpaced the prior year third quarter by 6% led by robust shipments in Brazil, Mexico and Vietnam. While shipments advanced versus the prior year, they were short of our earlier expectations leading to more inventory on hand throughout and at the end of the quarter. Since our last earnings release in mid-July, the impacts from inflation, European energy prices, interest rates and currency have become more challenging. With input costs expected to remain elevated prior to our contractual inflationary resets in 2023, and many customers adjusting their order patterns in response to lower consumer spending, we expect the operating environment and margins to remain under pressure for the balance of 2022. While the short-term environment is expected to remain challenging, we continue to focus on activities that will enhance our long-term success and remain confident in our outlook for 2023. Our global beverage can expansion projects remain on schedule, including both new two-line plants in the United States, with Martinsville, Virginia expecting to commence operations in November 2022 and Mesquite, Nevada in June 2023. The first line of our new facility in Uberaba, Brazil began commercial production in May and the second line earlier this month. The Company has begun construction on a multi-line facility in Peterborough, United Kingdom, with the first line scheduled to start up in June 2023. Additional production lines are being added to existing plants in Phnom Penh, Cambodia; Agoncillo, Spain; and Parma, Italy. Understanding we cannot control inflation or interest rates, we have focused on actions to lower costs for the current environment by reducing headcount and lowering capital spending. Additionally, in August, we extended our existing credit facility to August 2027, and raised an incremental $1.0 billion with the additional proceeds used to retire euro notes originally due in 2023. The balance sheet remains strong with no significant maturities until September 2024.

17:08 EDT Fannie Mae, Freddie Mac to require use of FICO Score 10 T - The Federal Housing Finance Agency has announced that FICO (FICO) Score 10 T has been validated and approved for use by Fannie Mae (FNMA) and Freddie Mac (FMCC). This decision means that FICO Score 10 T will be required to be used when available, as FICO is today, for each conforming mortgage delivered to the Enterprises.

17:02 EDT Sun Communities to increase rental rates in FY23 - The Company has sent notices to MH and annual RV residents and Marina members, and expects the following average rental rate increases for 2023: Manufactured Housing 6.2%-6.4%; Annual RV 7.7%-7.9%; Marina 7.3%-7.6%; and UK Operations 7.2%-7.4%.

16:52 EDT Cingulate executes MSA with Societal CDMO, provides clinical update - Cingulate (CING) announced it has executed a master services agreement, or MSA, with Societal CDMO (SCTL). With capabilities spanning pre-investigational new drug, or IND, development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms, Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate's lead candidate CTx-1301, an investigational medication for the treatment of Attention Deficit / Hyperactivity Disorder, or ADHD. Societal CDMO will dedicate a specific manufacturing suite within its Gainesville, Georgia facility and outfit it with proprietary equipment supplied by Cingulate. Cingulate is preparing to initiate a Phase 3 adult dose-optimization study later this year for its lead candidate, CTx-1301, to assess onset and duration of efficacy and safety in adults with ADHD. The study is expected to commence in December. In addition, CTx-1301 Phase 3 fixed-dose pediatric and adolescent safety and efficacy study is now expected to commence in mid-2023 after the final two dosage strengths for this study are completed by Societal CDMO. Assuming we receive positive clinical results from our Phase 3 trials and the food effect study with data expected in December, the company plans to submit a new drug application, or NDA, to the FDA in the first half of 2024 under the Section 505 pathway.

16:41 EDT BayCom announces stock repurchase program - BayCom announced that its Board of Directors approved its sixth stock repurchase program for the repurchase of up to 645,000 shares of its common stock, or approximately 5% of its outstanding shares, over a one year period through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934. The new stock repurchase program will commence upon completion of the fifth stock repurchase program. To date, the company has repurchased all of the 747,000 shares of company common stock authorized for repurchase pursuant to the fifth stock repurchase program.

16:35 EDT Range Resources sees FY22 holding production 2.12-2.16 Bcfe per day - The company said, "As previously noted, Range is targeting holding production approximately flat at 2.12 - 2.16 Bcfe per day, approximately 30% attributed to liquids production, with expectations at the lower end of guidance for the full year 2022 given timing of third-party infrastructure maintenance. Range's 2022 all-in capital budget is $460 million - $480 million with expectations at the upper end of the guidance."

16:32 EDT Asur reports Q3 total passenger traffic up 22.8% vs. 3Q19, up 24.5% y/y

16:22 EDT Hoth Therapeutics to effect 1-for-25 reverse stock split - Hoth Therapeutics announced that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on October 26, the company's common stock will trade on a post-split basis under the same trading symbol, "HOTH". As a result of the reverse stock split, the CUSIP number for the company's common stock will be 44148G204. The reverse stock split is primarily intended to bring the company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing; however, no assurance can be given that such reverse stock split will enable the company to regain compliance with the Nasdaq minimum bid price requirement.

16:21 EDT Guidewire announces strategic payments partnership with One Inc - Guidewire "announced One Inc as its strategic partner for payments to provide digital experiences that deliver flexibility and agility throughout the insurance lifecycle, from quote to claims payment. The One Inc and Guidewire partnership will empower insurers with an out-of-the-box joint solution that will enable the rapid delivery of a frictionless payment experience for customers, adjusters, agents, and vendors. As a PartnerConnect Solution Premier partner and a leading digital payments provider for the insurance industry, One Inc has more than 60 joint customers with Guidewire. The strategic partnership between Guidewire and One Inc now offers Guidewire InsuranceSuite and InsuranceNow customers an integrated payments solution that improves implementation speed and customer satisfaction. Guidewire and One Inc's partnership combines their insurance industry expertise, enabling insurers to deliver an end-to-end optimized experience for all insurance payment use cases."

16:19 EDT Middlefield Banc receives all necessary approvals for Liberty Bancshares merger - Middlefield Banc announced that it has received the necessary regulatory approvals to complete the proposed merger of Liberty Bancshares . Middlefield also announced that Institutional Shareholder Services recommends that Middlefield shareholders vote in favor of the proposed merger transaction. ISS is widely recognized as a leading independent voting and corporate governance advisory firm. ISS analyses and recommendations are relied on by many major institutional investment firms, mutual funds and fiduciaries throughout North America. On Friday, October 21 Middlefield received confirmation from the Federal Reserve Bank of Cleveland of a waiver of the obligation to file a bank holding company act application for approval of the acquisition of Liberty. The Ohio Division of Financial Institutions has issued approval for the merger of Liberty National Bank into The Middlefield Banking Company. All regulatory approvals required for completion of the merger have been received.

16:18 EDT Hexcel did not repurchase any common stock during Q3

16:16 EDT Hess Midstream Partners raises quarterly dividend by 1.2% to 56.3c per share - The distribution will be payable on November 14, 2022 to shareholders of record as of the close of business on November 3, 2022.

16:16 EDT Calix says 'robust' bookings, supply chain outperformance drove Q3 beat - The company said in its Q3 investor letter: "Robust bookings combined with supply chain outperformance led to the strong results in the quarter. We are seeing an acceleration in the number of new and legacy communication service providers and investors that are looking to become Calix platform-based Broadband Service Providers to simplify their businesses, excite their subscribers and grow their value for their members/investors and local community. The transformation of the service provider marketplace from builders of 'bumb' pipes to providers of a managed experience is gaining momentum and will likely continue for at least the next decade. Our unique platforms -Intelligent Access Edge, Revenue Edge and Calix Cloud - position us perfectly to help this next generation of BSPs succeed."

16:13 EDT Fluor awarded contract for imperial renewable diesel project in Canada - Fluor Corporation was awarded a reimbursable front-end engineering and detailed design, engineering and procurement services contract for Imperial as the company progresses plans to develop a world-class renewable diesel complex at its Strathcona refinery near Edmonton, Alberta, Canada. The new complex is expected to be the largest renewable diesel production facility in Canada and will produce approximately 20,000 barrels of renewable diesel per day from locally sourced feedstocks. Fluor booked the undisclosed contract value in the third quarter of 2022.

16:10 EDT Avadel announces new real-world narcolepsy data - Avadel Pharmaceuticals announced new real-world data identifying demographic characteristics and comorbidities of patients with narcolepsy. These results, along with three encore presentations, were presented at the American Neurological Association annual meeting, taking place October 22-25 "These data mark the first time we are analyzing aggregate information about patients with narcolepsy receiving treatment within the Mayo Clinic system over the last 20 years. More than 2,000 patients with narcolepsy were matched to a similar cohort, where we identified the top 20 comorbidities increased in people with narcolepsy, which were primarily mood, sleep and pain disorders," said Melissa Lipford, M.D., neurologist, Center for Sleep Medicine at Mayo Clinic and lead author on the abstract. "While the increased rate of mood and sleep disorders is well documented in the literature, understanding the increased prevalence of pain disorders is important, as we know that sleep and pain have a bi-directional relationship."The retrospective analysis was conducted in partnership with Mayo Clinic and real-world evidence vendor nFerence using electronic health records to identify people living with narcolepsy between 2000 and 2020 and describe their demographic characteristics and comorbidities. A matched control cohort was used to account for differences in demographics, care utilization and severity of illness. Highlights from the presentation are outlined below.

16:08 EDT Kontoor Brands raises quarterly dividend by 4% to 48c per share - The cash dividend will be payable on December 19, 2022, to shareholders of record at the close of business on December 9, 2022.

16:04 EDT Treasure Global receives noncompliance notice from Nasdaq - Treasure Global announced that it received notice from Nasdaq on October 20 notifying the company that it is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250 because the company's annual report on Form 10-K for the year ended June 30 was not filed with the Securities and Exchange Commission by the required due date of September 28.

15:57 EDT Middlesex Water increases common dividend by 7.76% to 31.25c per share - In a release issued on Oct. 21 by Middlesex Water, the company noted that the declared dividend increase is of 7.76% whereas the Friday version of this release listed it as 7.6%. Middlesex Water announced that its board of directors has declared a cash dividend of 31.25c per share on its common stock, an increase of 7.76% from the 29c per share dividend declared in July. The dividend is payable December 1 to shareholders of record as of November 16.

14:54 EDT Marqeta announces release of 'Marqeta for Banking' portfolio of products - Marqeta announced the release of "Marqeta for Banking," a portfolio of seven banking products that it says continues the expansion of the company's "modern card issuing platform." The company said: "Marqeta for Banking provides customers with a full set of account, ACH, instant funding and direct deposit products offered through Marqeta's bank partners, enabling them to build complete banking propositions for their end users on Marqeta's market leading platform. With Marqeta for Banking, businesses can utilize more than 40 new banking APIs and create customized banking services with the same level of flexibility and control provided by Marqeta's card issuing solutions. Marqeta for Banking includes new Demand Deposit Accounts, Direct Deposit with Early Pay, ACH with Plaid Integration, Cash Loads and Fee-Free ATMs, Bill Pay and Instant Funding capabilities... Similar to Marqeta's card issuing platform, Marqeta for Banking APIs were built from the ground up, providing customers the flexibility and speed they need to launch innovative banking propositions that appeal to consumers. With well-documented APIs, real-time data insights and a customizable platform, Marqeta for Banking customers can customize and deliver differentiated banking experiences to their users at scale."

14:21 EDT FTC takes action against Drizly, James Cory Rellas for security failures - The Federal Trade Commission announced it is taking action against the online alcohol marketplace Drizly and its CEO James Cory Rellas over allegations that the company's security failures led to a data breach exposing the personal information of about 2.5 million consumers. "Our proposed order against Drizly not only restricts what the company can retain and collect going forward but also ensures the CEO faces consequences for the company's carelessness," said Samuel Levine, Director of the FTC's Bureau of Consumer Protection. Boston-based Drizly, a subsidiary of Uber, operates an online marketplace where consumers of legal drinking age can place orders with retailers to buy beer, wine, and alcohol for delivery, the FTC noted. Reference Link

14:07 EDT Yum! enters agreement to transfer ownership of Russian KFC restaurant - Yum! Brands announced an update on its ongoing process to exit the Russian market. Yum! has entered into a sale and purchase agreement to transfer ownership of its Russian KFC restaurants, operating system and master franchise rights, including the network of KFC franchised restaurants, to Smart Service, operated by one of the company's existing KFC franchisees in Russia, Konstantin Yurievich Kotov and Andrey Eduardovich Oskolkov. Under the agreement, the buyer will be responsible for rebranding locations to a non-Yum! concept. In addition, the buyer will be responsible for retaining the company's employees in Russia. Completion of the transaction is subject to regulatory and governmental approvals, as well as other conditions agreed to by the parties. Following the completion of the transaction, Yum! will have ceased its corporate presence in Russia.

13:44 EDT Lithium Americas reports two contractor fatalities at Cauchari-Olaroz - The company said, "Lithium Americas is deeply saddened to report two fatalities at its Cauchari-Olaroz lithium project in Jujuy, Argentina on Sunday, October 23, 2022. The two separate incidents occurred at the camp and are not believed to be the result of workplace accidents. An investigation into the cause is underway and the authorities have been notified. Lithium Americas is working alongside our team at Cauchari-Olaroz to ensure proper support, including access to grief counselling services."

12:37 EDT Apple raises Music and TV+ subscription prices - Apple today is increasing the prices of its Apple Music and Apple TV+ subscription services along with the Apple One bundle. The Apple Music monthly price has been upped by $1 for individuals to $10.99 and $2 for families to $16.99. Apple TV+ is rising by $2 to $6.99 per month. Apple One for families is also going up by approximately $3 per month to $22.95. Apple told 9To5Mac: "The subscription prices for Apple Music, Apple TV+, and Apple One will increase beginning today. The change to Apple Music is due to an increase in licensing costs, and in turn, artists and songwriters will earn more for the streaming of their music. We also continue to add innovative features that make Apple Music the world's best listening experience. We introduced Apple TV+ at a very low price because we started with just a few shows and movies. Three years later, Apple TV+ is home to an extensive selection of award-winning and broadly acclaimed series, feature films, documentaries, and kids and family entertainment from the world's most creative storytellers."

12:05 EDT Microsoft's Bethesda says 'Fallout 4' next-gen update coming in 2023 - Bethesda, a game developer and publisher owned by Microsoft (MSFT), said that a next-generation console update is coming to role-playing game "Fallout 4," which first launched in late 2015. Coming in 2023, this free update will be available for Xbox Series X S, PlayStation 5 (SONY) and Windows PC systems, including performance mode features for high frame rates, quality features for 4K resolution gameplay, bug fixes and even bonus Creation Club content. Reference Link

12:01 EDT Aerojet Rocketdyne selected to power Navy's CRAW torpedo - Aerojet Rocketdyne will power the Navy's new Compact Rapid Attack Weapon as part of the Raytheon Missiles & Defense team building the next generation torpedo. Aerojet Rocketdyne will provide the afterbody, propulsion system and tail for the new torpedo.

12:00 EDT New Oriental Education falls -18.8% - New Oriental Education is down -18.8%, or -$4.29 to $18.50.

12:00 EDT ZTO Express falls -20.2% - ZTO Express is down -20.2%, or -$4.33 to $17.11.

12:00 EDT Pearson rises 9.4% - Pearson is up 9.4%, or 94c to $10.89.

11:42 EDT Republic First to continue to attempt constructive engagement with Norcross - The Board of Directors of Republic First Bancorp issued the following statement in response to the October 21, 2022 amended Schedule 13D filing and accompanying demand letter issued by George Norcross, III, Gregory Braca, Philip Norcross and Avery Conner Capital Trust and its trustees: "The Board, through its independent strategic review committee continues to run a full and fair strategic review process. At the same time, the Board is, also through independent committees, dutifully managing an internal investigation and shareholder demands that the demanding shareholders have linked to alleged actions of former directors and former CEO of the Company. These alleged actions of former directors and management have, among other things, delayed completion of the Company's financial statements audit and the filing of its Annual Report on Form 10-K for the year ended December 31, 2021. Despite the Board's best efforts to oversee the expeditious completion of the Company's financial statements and to continue diligently with its comprehensive Strategic Review, the Norcross Group has unfortunately decided to engage in public and distracting attacks against the Board...The Norcross Group's harmful behavior patterns call into question how George Norcross' and the Norcross Group's actions might reflect on the Company and affect the Company's employees and the communities that the Company serves. Further, these behaviors demonstrate why the Board must very carefully analyze whether any proposal from the Norcross Group would genuinely be in, and advance, the best interests of the Company, its shareholders and the other constituencies the Company serves, or if it would instead solely benefit the Norcross Group. Despite these real concerns, the Board, through independent committees, will nonetheless objectively and fully consider any alternatives and proposals submitted by the Norcross Group and will respond to the demands in the Norcross Filing in accordance with applicable law."

11:05 EDT BioSig signs master research agreement with Cleveland Clinic - BioSig Technologies announced that it will sponsor a research agreement with Cleveland Clinic Foundation to investigate expanded clinical applications for the intracardiac signals acquired by its PURE EP System. Under the terms of the research agreement, Cleveland Clinic will conduct physician initiated scientific research investigating PURE EP's potential to address common limitations of signal processing and signal use expansion during- but not limited to- electrophysiology ablation procedures. Results from this research could elucidate new clinical workflow methods impacting the ablation process for numerous arrhythmia types.

11:00 EDT RegeneRx licensee submits SPA to FDA for fourth Phase 3 clinical trial - RegeneRx Biopharmaceuticals reported that its U.S. joint venture partner and licensee, HLB Therapeutics, has announced that it submitted a request for the Special Protocol Assessment to the U.S. FDA for an in-depth discussion and assessment of the clinical protocol for a fourth phase 3 clinical trial for the treatment of dry eye disease. RGN-259 is a sterile, preservative-free, eyedrop being developed by ReGenTree, a U.S. joint venture company between RegeneRx Biopharmaceuticals and HLB Therapeutics. "In accordance with our SPA request, we have submitted to the FDA a briefing document summarizing our ARISE-1, -2, and -3 clinical data, including efficacy parameters and questions related to the clinical development of RGN-259 dry eye, along with the ARISE-4 protocol and statistical analysis plan. It is expected that the detailed direction and agreement given by FDA in advance by using the SPA process will help the company's development strategy for the approval of RGN-259. Considering the initiation of this process, we expect that the ARISE-4 trial will begin around the second quarter of 2023," according to HLB Therapeutics.

10:00 EDT TAL Education falls -19.5% - TAL Education is down -19.5%, or -77c to $3.17.

10:00 EDT Myovant Sciences rises 8.4% - Myovant Sciences is up 8.4%, or $2.06 to $26.60.

10:00 EDT Amprius Technologies rises 9.8% - Amprius Technologies is up 9.8%, or $1.08 to $12.19.

09:47 EDT XPeng falls -14.9% - XPeng is down -14.9%, or -$1.21 to $6.92.

09:47 EDT D-Wave Quantum rises 6.0% - D-Wave Quantum is up 6.0%, or 29c to $5.09.

09:47 EDT Pearson rises 8.6% - Pearson is up 8.6%, or 86c to $10.82.

09:43 EDT Sunrise New Energy develops new process for manufacturing silicon-based anode - Sunrise New Energy has developed a new process for the manufacturing of silicon-based anode that reduces the cost to build a manufacturing facility by 80% and reduces the cost of the finished silicon-based anode product by 50% compared to current manufacturing processes. Silicon-based anode is universally accepted as the successor to graphite anode found in today's lithium-ion EV batteries because it has 4x the capacity, which is 1500mAh/g compared to 370 mAh/g. These next-generation batteries using silicon-based anode will double the range of EVs without increasing weight. However, despite the huge advantages that silicon-based anode will bring to EVs, the current cost to manufacture silicon-based anode would dramatically increase the cost of already expensive EV batteries, making them economically unviable for all but very high-end vehicles. Sunrise's breakthrough will bring the cost of these next-generation, long-range batteries sharply down to a slight premium to current lithium-ion batteries. "This breakthrough on the manufacturing of silicon-based anode is a huge positive, not just for Sunrise but also for consumers, as it will eliminate range anxiety that is keeping some of them from switching to EVs. Our major clients gave highly praise and expressed strong interests over our silicon-based anode products." said Sunrise's Chairman, Mr. Haiping Hu. "We plan on becoming the world's largest and best manufacturer of anode materials for EV batteries and as such developing industry leading technology for the manufacturing of next-generation anode was a very important step."

09:42 EDT Tricida trading resumes

09:37 EDT Tricida trading halted, volatility trading pause

09:26 EDT Vitru announces commencement of rights offering - Vitru announced that it has commenced its previously announced rights offering. Pursuant to the Rights Offering, Vitru is distributing nontransferable subscription rights to each holder of its common shares as of 5:00 p.m., Eastern Time, on October 21, 2022. The subscription rights may be exercised at any time during the subscription period, which commences on October 24, 2022, and ends at 5:00 p.m., Eastern Time, on November 17, 2022. The subscription rights will expire and will have no value if they are not exercised by the Expiration Date. One subscription right is being distributed for each six common shares held as of the Record Date, with each subscription right exercisable for one common share at an exercise price of U.S.$16.02 per full common share. Vitru will not issue any fractional shares upon exercise of any subscription rights in the Rights Offering, and shareholders must exercise subscription rights which would result in the issuance of at least one whole common share to participate in the Rights Offering. For example, if you owned 1,000 of our common shares on the Record Date, you would be granted subscription rights to purchase an aggregate of 166 of our common shares at the subscription price per share. An aggregate of up to 4,818,123 common shares are issuable pursuant to the Rights Offering. Vinci Capital Partners II J Beta Fundo de Investimento Em Participacoes Multiestrategia, Agresti Investments LLC, Botticelli Investments LLC, Caravaggio Investments LLC and Raffaello Investments, along with Mundi Holdings I, Mundi Holdings II, and NB Verrocchio LP have advised us that they will not exercise any subscription rights issued to them pursuant to the Rights Offering. If the Rights Offering is fully subscribed by all other shareholders, it would raise gross proceeds of approximately U.S.$32.2 million. Vitru currently intends to use the net proceeds from the Rights Offering to repay a part of the aggregate principal amount outstanding under our Series 1 Debentures due 2024 and our Series 2 Debentures due 2027. In addition, Vitru intends to use any remaining net proceeds from the Rights Offering for general corporate purposes.

09:21 EDT Meta called on by investor Altimeter Capital to cut headcount, slow spending - Altimeter Capital Chairman and CEO Brad Gerstner said in an open letter to Meta Platforms and CEO Mark Zuckerberg that the company has too many employees and is moving too slowly to retain the confidence of investors. Gerstner said in the letter: "Meta needs to get its mojo back. Meta needs to re-build confidence with investors, employees and the tech community in order to attract, inspire, and retain the best people in the world. In short, Meta needs to get fit and focused. To accomplish this goal, we recommend a three step plan that will double FCF to $40 B per year and focus the company's teams and investments: Reduce headcount expense by at least 20%; Reduce annual capex by at least $5 B from $30B to $25B; and Limit investment in metaverse / Reality Labs to no more than $5B per year." The executive added that "People are confused by what the metaverse even means. If the company were investing $1-2B per year into this project, then that confusion might not even be a problem." Gerstner concluded by saying: "We don't have any demands. We simply wanted to further engage and continue sharing our thoughts as an interested shareholder. We believe in this team. We know Meta has more reach, more relevance, and more incredible opportunities for growth than almost any platform on the planet. And we are confident that your long-term investments in AI and the next generation of communications will continue to drive us all forward." Reference Link

09:20 EDT East Stone Acquisition files proxy statement for NTWN combination - East Stone Acquisition and NTWN announced East Stone's filing with the U.S. Securities Exchange Commission of a definitive merger proxy statement to hold a special meeting in lieu of an annual meeting of its shareholders on November 7, 2022 at 9:00 am Eastern Time, to consummate its initial business combination with NWTN. The Merger Proxy Statement and related materials are being delivered today to holders of record as of October 4, 2022.

09:13 EDT BYND Cannasoft, Matrix Mediak to explore further FDA development of EZ-G - BYND Cannasoft Enterprises announced that it entered into a consulting service with Matrix Medika. The service will be given as part of the agreement with Arkit Studio, a company that provides the service of characterization and design for the EZ-G Device. Matrix Medika will assist BYND Cannasoft by granting opinion and market research about the regulatory approval process for the Company's EZ-G device in Europe and the US, including FDA regulation, should such approval be required. After receiving the opinion, BYND Cannasoft will extend the consulting service with Matrix Medika for all phases of development of its EZ-G device from inception to include planning, design, development, and testing. BYND Cannasoft intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device. The Company's 'Go to Market' strategic plan is based on both B2B and B2C sales. Yftah Ben Yaackov, CEO and Director of BYND, said, "Our commitment to our shareholders is to bring the EZ-G device to market as quickly as possible. Matrix Medika has worked with numerous medical companies and startups to assist them with getting high-quality healthcare projects and software to market quickly and within budget. Some of the companies currently listed on Matrix Medika's website include McKesson, NovelDSP, Sanara Ventures, Vibrant, Next Generation Technologies, and Novoxel. We believe their expertise in medical and technological regulation will allow us to bring the EZ-G device to market in a much more expeditious manner than we could on our own."

09:10 EDT Data Storage achieves ISO/IEC 27001 certification for CloudFirst, Nexxis - Data Storage Corporation announced that its CloudFirst and Nexxis divisions have been ISO/IEC 27001:2013 certified.

09:09 EDT Adobe to aid U.S. Bancorp enhance online and in-branch customer experience - Adobe (ADBE) announced it is working with U.S. Bank (USB) to deliver enhanced online and in-branch customer experiences that are personalized to individuals' needs and interests. The collaboration will build upon the successful digital transformation at U.S. Bank, which allows customers to have a consistent experience across branches and on web and mobile platforms, empowering them to complete bank transactions in a way that fits their needs. This could mean a conversation with a banker to discuss a financial plan, as well as depositing a check or checking a balance on the U.S. Bank Mobile App. Currently, more than 80% of U.S. Bank consumer transactions and nearly 65% of loan sales are being handled digitally. With so many touchpoints, the Adobe Experience Platform will help deliver a single view of the customer, providing the marketing organization greater precision in providing timely and appropriate content through the right channel.

09:08 EDT AMD to unveil next generation EPYC processors during upcoming event - AMD announced "together we advance_data centers," an in-person and livestreamed event to unveil the next generation of AMD EPYC data center processors. AMD executives, along with other key ecosystem partners, will present details on the next generation data center processor and solutions.

09:05 EDT Electromed appoints Brad Nagel CFO - Electromed announced that its Board of Directors has appointed Brad Nagel as the Company's Chief Financial Officer, effective November 14. Nagel brings to Electromed over fifteen years of financial leadership and strategic planning experience with Fortune 500 companies. Most recently, Mr. Nagel held the position of Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic and was a key contributor in driving the unit's revenue growth. In that role, he served as the primary business partner to the General Manager and leadership team with a strategic focus on revenue growth, expense management, strategic product development and business development. Prior to his role as Divisional Chief Financial Officer, Mr. Nagel held various roles of increasing responsibility in finance, sales operations and accounting at Medtronic, Target Corporation and TCF Bank. "We are thrilled to welcome Brad to the Electromed team," Kathleen Skarvan, Electromed's President and Chief Executive Officer, commented. "Brad is a dynamic financial executive with a superior track record of engineering growth and creating value in the medical device and retail industries. Through collaborative and cross-functional leadership, Brad has proven to be a high-impact leader with extensive background in developing high-performing teams. His financial, analytical and strategic acumen coupled with his leadership style makes Brad a strong cultural fit at this time when Electromed is poised for accelerating growth. I am confident he will be an excellent addition to the leadership team."

09:04 EDT Biora Therapeutics presents five posters at ACG annual meeting - Biora Therapeutics announced the five posters presented at the American College of Gastroenterology 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 21-26, 2022. At the ACG meeting, the company presented detailed results from two human trials for its targeted therapeutics platform that were performed first in healthy patients and subsequently in active ulcerative colitis patients. In posters titled "A scintigraphic study to evaluate the safety, tolerability, and functionality of a Drug Delivery System device in healthy volunteers in fasted state" and "A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System device in patients with active ulcerative colitis in fasted state," researchers found that the DDS device was well tolerated and functioned as intended in autonomously identifying colon entry and releasing a radioactive payload in the colon. In the poster titled "Pilot study to assess pharmacokinetic and pharmacodynamic markers following enema-dosing with adalimumab in patients with active ulcerative colitis," researchers at Mater Hospital Brisbane, Royal Adelaide Hospital, and Biora Therapeutics assessed pharmacokinetic and pharmacodynamic parameters following dosing with an adalimumab enema in patients with active UC, to evaluate whether topical treatment with adalimumab may be beneficial for treatment of UC. Biora Therapeutics also presented two posters presenting preclinical data on its systemic therapeutics platform, titled "Development of ex-vivo and in-vivo models to assess the performance of an oral biotherapeutic delivery system device" and "Evaluation of the pharmacokinetics of PGN-OB1 following oral administration of an oral biotherapeutics delivery system in Yucatan swine."

09:02 EDT Weatherford receives five-year contract exceeding $500M from PDO - Weatherford International received a five-year contract exceeding $500 million from Petroleum Development Oman, PDO, to deliver Integrated Drilling Services in the Marmul and Grater Saqar fields. Operations are targeted to begin in the fourth quarter of 2022. Weatherford Integrated Drilling Services will combine a suite of technologies to deliver holistic and innovative solutions that maximize drilling efficiency in PDO's Marmul and Grater Saqar Fields. This project is an integral part of Weatherford Oman's In Country Value strategy and also in line with Oman's Vision 2040 to deliver safe and sustainable energy for the future. Weatherford President and Chief Executive Officer Girish Saligram commented, "Our Integrated Services offering is gaining significant traction in the market. This award builds on our long and proven history of delivering technology leadership and innovation and is a testament to the competitiveness of our portfolio. We are looking forward to further strengthening our relationship with PDO as we support their operations in this critical project. Our service quality, value proposition, and local content positioned Weatherford as the clear partner of choice and will enable safe drilling operations that maximize efficiency while delivering value and reducing carbon emissions."

08:56 EDT ACNB Corp raises quarterly cash dividend to 28c per share - ACNB Corporation announced that the Board of Directors approved and declared a regular quarterly cash dividend of $0.28 per share of ACNB Corporation common stock payable on December 15, 2022, to shareholders of record as of December 1, 2022. This per share amount reflects a 7.7% increase over the same quarter of 2021 and will result in aggregate dividend payments of approximately $2.4 million to ACNB Corporation shareholders in the fourth quarter of 2022. Compared to a year ago, ACNB Corporation paid a $0.26 dividend per common share in the fourth quarter of 2021.

08:51 EDT American Resources receives approval of deep cut plan at Carnegie 1 - American Resources announced that it has been approved by the Mine Safety and Health Administration for a deep cut plan at its Carnegie 1 mine. The McCoy Elkhorn Complex was formerly a complex owned and ran by James River Coal as one of their premier facilities in the region. The complex is one of the last high-quality long-life mining facilities in the market and in the region. The hub and spoke facility is centered around two state of the art processing plants and a 110 car unit train rail load out facility and two fully approved and permitted impoundments that can process north of 6 million tons of carbon per year. Post the start of its next two mines, the Company will begin the planning of the next phase of organic growth from the McCoy Elkhorn complex.

08:48 EDT Altamira Therapeutics announces 1-for-20 reverse stock split - Altamira Therapeutics announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20. The reverse stock split is expected to become effective at market opening on October 25, 2022, and the shares to begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "CYTO." The new CUSIP number following the reverse stock split will be G0360L209. The reverse stock split is primarily being effected to regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.As a result of the reverse stock split, every 20 shares of the Company's issued and outstanding common shares will automatically combine into one issued and outstanding common share. The reverse stock split will affect all shareholders uniformly and will not alter any shareholder's percentage ownership interest in the Company. Proportionate voting rights and other rights of shareholders will not be affected by the reverse stock split. The reverse stock split will also apply to common shares issuable upon the exercise of the Company's outstanding warrants. In accordance with the 1-for-20 ratio, the number of authorized common shares will be reduced to 5,000,000 while the par value will be increased to CHF 0.20 per common share. As a result of the reverse stock split, the number of common shares outstanding will be reduced from approximately 21.5 million to approximately 1.1 million, subject to rounding down of all fractional shares to the nearest whole share and the payment to shareholders of cash in lieu of such fractional shares.

08:44 EDT Optex Systems announces $720,000 order for MPF support - Optex Systems Holdings announced it has been awarded a $720,000 order from a major US Prime Contractor in support of the US Army's Mobile Protected Firepower tank program. The majority of this work will be performed in the Richardson facility.

08:40 EDT One Stop Systems to deliver ruggedized compute solutions for Embark - One Stop Systems (OSS) has secured two new autonomous truck program wins with Embark Trucks (EMBK). The two wins include one for OSS' Centauri rugged PCIe storage expansion system and another for OSS' next-generation optimized autonomous truck 3U SDS rugged accelerated computing server, 3U SDS-AT. The new wins involve equipping trucks from Embark's test fleet with the highest-performance ruggedized compute and transportable storage capabilities. OSS worked closely with Embark and other customers to define the attributes and inform the design of the next-gen 3U SDS that would make it ideal for the autonomous truck market. Leveraging Embark's industry experience and feedback, OSS included attributes such as additional ruggedization and more efficient air cooling, system monitoring and I/O-all elements critical to the commercial operation of autonomous long-haul trucks. "These additional wins reaffirm our belief that OSS is delivering the best solutions for autonomous long-haul trucking on the market today," stated David Raun, OSS' president and CEO. "This third win for our 3U SDS platform demonstrates our expert ability to ruggedize datacenter-class compute and storage solutions and ensure the highest level of durability required by today's autonomous trucks. Our solutions also provide secure system monitoring and control, ground-breaking cooling technologies, and PCI Express scalability that supports a variety of trucks with varying amounts of sensors."

08:39 EDT Blackstone and Dominium to develop the Aviara Flats in Phoenix, Arizona - Blackstone announced a partnership to develop the Aviara Flats community that will bring 372 new affordable housing units to Phoenix, Arizona. As part of this partnership, Blackstone will provide $48M of tax credit equity to support the development of these units. The property is located an approximately 15-minute drive from Downtown Phoenix and units will be available to households earning at or below 60 percent of the area median income. Aviara Flats will feature a number of community amenities including a gym, playground, clubroom, pool and theater. "We are excited to partner with Blackstone and April Housing to deliver on our shared commitment to address the shortage of affordable housing in the U.S.," said Mark Moorhouse, Dominium Managing Partner & Executive Vice President. "Since breaking ground in June, we have made great progress on the development of the property and look forward to working with April to complete Aviara Flats in 2024. April's knowledge and approach to LIHTC investment is impressive, and Dominium could not be more excited about their involvement in the tax credit space."

08:38 EDT Scynexis presents data of oral ibrexafungerp from ongoing Phase 3 FURI study - SCYNEXIS announced the presentation of cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated with oral ibrexafungerp from the ongoing Phase 3 FURI study. The analyses were presented during IDWeek 2022 held in Washington, D.C., October 19-23, 2022. FURI Outcomes by Fungal Disease Type: Ibrexafungerp demonstrated a favorable therapeutic response for the majority of patients with a variety of serious fungal infections who have failed or are intolerant to currently available treatments or for whom currently available oral antifungals are not adequate due to resistance and IV therapy is no longer feasible or desirable. Of these patients, the most common fungal disease was invasive candidiasis/candidemia in 56, followed by severe mucocutaneous candidiasis in 32, refractory vulvovaginal candidiasis in 14, and invasive aspergillosis in 11. Complete or partial response was reported in 62.5% of patients with IC with an additional 23.2% reporting stable disease. For patients with severe mucocutaneous candidiasis, 53.1% reported complete or partial response and 34.4% reported stable disease. All-Cause Mortality in Patients with Invasive Candidiasis: All-cause mortality outcomes through 30 days post completion of ibrexafungerp treatment was presented as a poster. Fifty-six of 113 FURI patients in this data set had a diagnosis of invasive candidiasis or candidemia. In this population with difficult to treat fungal infections with limited treatment options, the most common pathogens were Candida glabrata, C. albicans, C. krusei and other non-albicans Candida species. Ibrexafungerp Pipeline Update: In addition, Nkechi Azie, M.D., Vice President, Clinical Development and Medical Affairs at SCYNEXIS, presented an ibrexafungerp pipeline update during the New Antimicrobials and ID Diagnostics in the Pipeline - Fungal session at the conference.

08:36 EDT Bebuzee adds digital wallet component into Super App - Bebuzee is incorporating a digital wallet service into its Super App. The integrated Digital Wallet gives the Company one of the key & necessary components that have helped drive Southeastern Asia Super Apps to their multibillion-dollar prominence. Bebuzee's App may be the first super app produced in and aimed at users in the West.

08:35 EDT Vista Outdoor: Spin-off of Outdoor Products unit on track for calendar 2023

08:34 EDT Mirum Pharmaceuticals announces Livmarli study achieves primary endpoint - Mirum Pharmaceuticals announced topline results from its pivotal Phase 3 MARCH study evaluating Livmarli oral solution in 93 patients with progressive familial intrahepatic cholestasis, or PFIC, in a broad range of subtypes, age one to 17 years. The primary endpoint of improvement in pruritus severity in PFIC2 was statistically significant. The primary analysis was conducted in PFIC2 patients (n=31). The secondary analyses were evaluated in the All-PFIC cohort, which included PFIC2 as well as additional PFIC subtypes. The Full-Study population included All-PFIC as well as supplemental patients who had previously undergone surgery, had truncating mutations and other patients. Livmarli's safety and tolerability profile was comparable to previously published data and no new safety signals emerged in the MARCH study. The most common treatment emergent adverse event was diarrhea, which was predominantly mild, with no severe cases, and transient with a median duration of 5.5 days. One patient had a treatment emergent adverse event of mild diarrhea that led to discontinuation. Further data from the MARCH study will be presented at an upcoming scientific conference.

08:34 EDT Rani Therapeutics announces new RT-111 development program, provides update - Rani Therapeutics (RANI) announced the preclinical development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar, as part of a corporate and pipeline update. Ustekinumab, approved in the United States as STELARA, is used for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis, all of which have large unmet medical needs for oral treatment. Pipeline Updates: RT-111: Rani has begun preclinical development with RT-111, a RaniPill GO capsule containing a biosimilar of STELARA; STELARA is an interleukin-12 and interleukin-23 antagonist marketed by Janssen Biotech (JNJ) with sales of approximately $5.9 billion in the United States and approximately $9.1 billion worldwide in 2021.RT-102: In August 2022, Rani announced positive topline results from Part 1 of its Phase 1 study of RT-102, meeting all of its endpoints while being generally well-tolerated; and Rani anticipates announcing topline data from Part 2 of the Phase 1 study of RT-102, which will be the first repeat-dose data of the RaniPill capsule in humans, in the fourth quarter of 2022. RaniPill HC: Rani is continuing development of the RaniPill HC; Rani intends to conduct in vivo studies with a fully-autonomous RaniPill HC in the fourth quarter of 2022. Repeat-Dose Studies: Rani will not be initiating a separate repeat-dose platform study in 2022. Rani incorporated repeat dosing into the design of its Phase 1 study of RT-102 and expects to obtain longer term repeat-dose data in a Phase 2 study of RT-102 planned for 2023. RT-109: Following a strategic priority review, Rani has decided not to continue active development of RT-109, a RaniPill capsule containing human growth hormone. Updated Milestone Expectations: RT-102 - Phase 1 Part 2 topline repeat-dose data expected in the fourth quarter of 2022. RT-102 - Investigational New Drug application, followed by Phase 2 initiation in the second half of 2023. Initiation of three additional Phase 1 studies in 2023 with pipeline molecules - RT-105, RT-110 and RT-111.

08:29 EDT Lexagene Holdings enters into secured convertible note agreement - LexaGene Holdings announces that it has entered into a secured convertible note agreement with Meridian LGH Holdings 2, an affiliate of an insider of the Company, in the aggregate principal amount of up to USD$1,600,000. The Note bears interest at 12% per annum and matures on March 1, 2023, subject to an increased interest rate of 16% if the Company commits an event of default and such default continues, in accordance with the Note Agreement. Subject to TSX Venture Exchange approval, the outstanding principal of the Note is convertible into common shares of the Company at a conversion price of USD$0.17, the last closing market price of the Shares on the TSXV prior to the date of this press release. Interest on the Note will be convertible at the market price of the Shares on the TSXV at the time the interest is due and payable, subject to TSXV approval. The Company may prepay the Note, and any accrued interest, at any time without penalty. In the event the Company undertakes an equity financing of at least USD$5 million or undertakes a merger, amalgamation, sale of substantially all of its assets or similar corporate transaction, Meridian may accelerate the maturity date of the Note and require the Company to repay the outstanding principal amount of the Note and accrued and outstanding interest. The Note will be secured against the assets of the Company and will be guaranteed by the subsidiaries of the Company.

08:28 EDT Aquestive Therapeutics announces court dismisses all claims in Suboxone suit - Aquestive Therapeutics announced that the United States District Court for the Eastern District of Pennsylvania entered an order on October 19, 2022 dismissing all claims against Aquestive in the Suboxone antitrust lawsuit brought by a group of States' Attorneys General against Indivior and Aquestive, Case No. 16-cv-5073. "We are pleased that the Court has granted our summary judgment motion and agreed to dismiss all claims against Aquestive related to the ongoing litigation associated with this case, establishing that the Company should never have been named in the lawsuit. This judgment is another step forward in improving our business," said Daniel Barber, Chief Executive Officer of Aquestive. "With this decision, we will continue to focus our efforts on advancing our pipeline and preparing for our upcoming End-of-Phase 2 meeting with the FDA for our lead program AQST-109 for the treatment of severe allergic reaction, including anaphylaxis."

08:24 EDT IGEN Networks announces exclusive marketing agreement with ASEC - IGEN Networks announced an exclusive marketing agreement with the Association of Credit Union Executives of Puerto Rico, ASEC. This agreement will enable ASEC and Credit Unions to generate new revenue streams in marketing IGEN's CU Trak and FamilyShield to their members and families. In conjunction with the U.S. Department of Treasury's Community Development Financial Institutions, CDFI, Fund, which has granted $13.2M to 105 Credit Unions and Cooperatives for Technical Assistance in 2022 thus far, the CDFI Fund will provide the financial assistance to Credit Unions to utilize CDFI qualified technologies for the benefit of their members. "IGEN Networks sponsorship and participation at ASEC's annual meeting in Punta Cana, Dominion Republic was a huge success. Although Credit Unions have heard of similar technologies in the past, no company has ever focused on addressing the specific technology needs of Credit Unions and automotive financing like we have. IGEN has developed products like CU Trak with ASEC in Puerto Rico in anticipation of further expansion into Latin America and further partnerships with ASEC affiliated organizations like the CUNA Mutual Group," said Abel ISierra, Chief Operating Officer of IGEN Networks Corporation.

08:22 EDT FactSet, Agencia Estado partner to deliver financial news to Brazilian market - FactSet announced its strategic partnership with Agencia Estado, the leading real-time news and market data vendor in Brazil. The partnership integrates Agencia Estado's Portuguese-language newswire into FactSet's flagship workstation to create the Broadcast+ FactSet Workstation, a co-branded solution combining local Brazilian news and content from Agencia Estado with FactSet's award-winning data, analytics, and technology services. Helen Shan, Executive Vice President, Chief Revenue Officer at FactSet, said: "Our partnership with Agencia Estado represents an important milestone in FactSet's expansion into the Brazilian market, and advances our strategy to partner with other leading companies to provide solutions that meet the evolving needs of the global business community."

08:20 EDT Aziyo Biologics appoints David Colpman to board of directors - Aziyo Biologics announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022. His appointment brings the company's Board of Directors to six members. Colpman was the managing partner of Colpman Consulting Ltd., a business development consultancy, from July 2014 to March 2020.

08:18 EDT Applebee's announced that Chef Scott Rodriguez named Chief Culinary Officer - Applebee's announced that Chef Scott Rodriguez has joined its leadership team as Senior Vice President and Chief Culinary Officer. A classically trained chef, Rodriguez brings deep casual dining innovation experience to Applebee's talented culinary team.

08:16 EDT Morphic completes enrollment of EMERALD-1 main cohort - Morphic Therapeutic announced the completion of targeted enrollment of 30 patients ahead of schedule for the main cohort of the EMERALD-1 phase 2a study of MORF-057 in patients with moderate to severe ulcerative colitis. Based on the rapid enrollment and substantial demand accrued to enter EMERALD-1, there were a significant number of patients in screening at the time of the 30th patient's enrollment; these patients will be eligible to enter the study if the eligibility criteria are met. Enrollment in the exploratory cohort of up to ~10 patients who have previously failed treatment with vedolizumab is ongoing.

08:16 EDT XpresSpa announces new corporate identity - XWELL (XWEL), formerly XpresSpa Group (XSPA), announced a corporate rebranding of the Company to XWELL. XWELL unveiled a new visual identity and website, in connection with the rebrand, and the Company's Nasdaq ticker symbol will change from "XSPA" to "XWEL," effective before the market opens on October 25, 2022. The new name emphasizes the Company's ongoing transformation and expansion of its health and wellness offerings. XWELL's suite of brands will continue to operate under their existing names including XpresSpa, Treat, XpresCheck, and HyperPointe. "We're focused on growth with a vision to be a leading provider of innovative health and wellness products and services for people on the go," said XWELL chief executive officer Scott Milford. "The new name, XWELL, aligns with our shift towards health and wellness and marks a key milestone in the Company's transformation." Milford added, "Today, XpresSpa Group seamlessly evolves into XWELL and emerges as a global health and wellness authority for people on the go. We firmly believe the Company is well positioned to deliver on its long-term objectives."

08:14 EDT Phathom completes patient enrollment in Phase 3 PHALCON-NERD-301 trial - Phathom Pharmaceuticals announced it has completed enrollment in its PHALCON-NERD Daily Dosing Phase 3 trial of vonoprazan in non-erosive gastroesophageal reflux disease. Vonoprazan is an investigational first-in-class potassium-competitive acid blocker from a novel class of medicines that block acid secretion in the stomach. The Company expects to share topline data from the primary endpoint in the first quarter of 2023 and full results from the study in late 2023. If successful, Phathom believes that the trial will form the basis of a supplemental New Drug Application for vonoprazan as once daily therapy for the treatment of symptomatic NERD in adults in 2023. The primary endpoint of the double-blind Phase 3 PHALCON-NERD-301 study is evaluating the efficacy of vonoprazan 10 mg and 20 mg as a daily dosing treatment, as compared to placebo, in the relief of heartburn over four weeks in participants with symptomatic NERD. The trial also includes a unique blinded 20-week long-term extension period to further evaluate the safety and efficacy of both doses of vonoprazan after six months.

08:11 EDT Pear Therapeutics publishes results from reSET analysis - Pear Therapeutics announced the publication of results from a real-world observational analysis of engagement, retention and substance use among patients with substance use disorder, or SUD, treated with reSET, the first and only FDA-authorized PDT for the treatment of SUD. The real-world data, which demonstrated high rates of engagement, retention1 and abstinence from substances with reSET treatment through 12 weeks, was published in The American Journal on Addictions, or AJA. The real-world observational analysis was conducted in an all-comer population of 602 patients with SUD treated with reSET over 12 weeks. Substance use was evaluated as a composite of self-reports and urine screens. Summary of results: Over 74% of patients were retained in reSET treatment and continued to use their PDT during the last four weeks. Abstinence rates during the last four weeks were 62% where missing data was treated as a positive urine screen and 86% where the missing data was excluded from the analysis. Of the patients using reSET appropriately 81% were abstinent and 92% were retained at 12 weeks.

08:10 EDT Finexio closes $35M Series B funding round - Finexio announces the completion of an oversubscribed $35M Series B funding round at a $100 million pre-money valuation. Mendon Venture Partners and National Bank Holdings Corporation (NBHC) co-led the financing. J.P. Morgan (JPM) was the largest investor in the growth round. Existing fintech investor Patriot Financial Partners participated in addition to new investors Discover Financial Services (DFS), Valley Bank (VLY), Trogg Hawley Capital LLC, and other leading financial services and fintech C-suite executives.

08:09 EDT Heliogen receives $4.1M award from the Department of Energy - Heliogen announced that it has been selected to receive a $4.1M award from the U.S. Department of Energy Solar Energy Technologies Office to accelerate the large-scale development and deployment of concentrating solar-thermal power technology for industrial decarbonization and electrical power generation and storage. This project will aim to demonstrate a first-of-its-kind concentrating solar-thermal power process for decarbonizing the heating of limestone to 950 degrees C, which could reduce the carbon emissions associated with cement manufacturing.

08:07 EDT Beyond Meat debuts Beyond Steak - Beyond Meat (BYND) announced the launch of Beyond Steak, a new innovation designed to deliver the juicy, tender and delicious bite of seared steak tips with the added nutritional and environmental benefits of plant-based meat. Beyond Steak is launching at Kroger (KR) and Walmart (WMT) stores nationwide, as well as at select Albertsons (ACI) and Ahold divisions and other retailers across the country.

08:06 EDT FIS announces Walmart joins Premium Payback - FIS (FIS) has announced that Walmart (WMT) is joining Premium Payback, the financial technology company's real-time rewards redemption network. The addition of Walmart to the Premium Payment network will give millions of consumers the opportunity to redeem their credit card rewards points for real-time discounts at more than 4,700 Walmart stores across the U.S. Walmart customers using eligible cards will be prompted at checkout with the option to turn their card rewards currency into discounts, which will be deducted from their purchase amount.

08:05 EDT Enochian forges ahead with focused approach, files complaint against Gumrukcu - Enochian BioSciences announced significant progress toward re-prioritizing its focus on curing some of the world's deadliest diseases. Last week, the Company announced its oncology platform was awarded a U.S. patent and has produced promising early results in studies conducted in conjunction with Dr. Ana Jewett at UCLA. The Company also awaits potentially positive results from studies on its HIV platform, which are being conducted by scientists at the Fred Hutchinson Cancer Center. The Company also announced it filed a complaint against Serhat Gumrukcu, William Anderson Wittekind, SG & AW Holdings LLC, and Seraph Research Institute in the California Superior Court for Los Angeles County. As alleged in the complaint, the defendants engaged in a "concerted, deliberate scheme to alter, falsify, and misrepresent to [the Company] the results of multiple studies supporting its [Hepatitis B] and SARS-CoV-2/influenza pipelines." "Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth. Defendants' conduct amounts to nothing short of brazen fraud, which has caused Enochian substantial harm." Through this lawsuit, the Company "intends to hold [the] Defendants responsible for their conduct and recover damages resulting" from their actions.

08:03 EDT Koppers Holdings' Chemical subsidiary announces $40M in new business - Koppers Holdings' wholly-owned subsidiary Koppers Performance Chemicals, or PC, announced a significant expansion of market share in industrial and commercial wood preservation technology markets. Recent regulatory actions in both the U.S. and Canada have resulted in the phase out of pentachlorophenol, a longstanding oil-borne preservative that made up approximately 40% of the industrial wood preservative market for treating utility poles. PC assisted treaters with transitioning from penta to either its legacy K-33 CCA water-borne preservative or its newest entry into the oil-borne preservative field, InPro 23 and InPro 50 DCOI, which Koppers began offering in mid-2022. In a few short months, PC has secured approximately $40M of annualized new industrial business, adding 14 new customers across 18 locations for its CCA and DCOI products.

08:02 EDT BIMI International enters definitive agreement for disposal of assets in China - BIMI International Medical announced that it has entered into a definitive sale and purchase agreement to sell its wholly-owned subsidiary, Chongqing Zhuoda Pharmaceutical, a distributor of pharmaceuticals and biologicals located in China to three citizens of China who previously sold Zhuoda to the Company. The initiative is in line with the Company's business strategy to dispose of underperforming assets in China to support its expansion in the United States. Pursuant to the Agreement, the Company will sell 100% of the equity interests in Zhuoda that it previously purchased for 440,000 shares of the Company's common stock, which purchase price was subject to post-closing payments based on performance in 2022 and 2023. The 440,000 shares will be returned to the Company as the full consideration of the sale of the interests in Zhouda. The closing of the Agreement is expected to take place late in the fourth quarter of 2022, subject to necessary regulatory approvals. Tiewei Song, Chief Executive Officer of BIMI International Medical Inc., commented, "We are excited to sign the Agreement as it represents our goal to focus on enhancing our operations and executing a growth plan for the future. The transaction illustrates our core capabilities of disposing of underperforming assets, optimizing asset allocation and adjusting the Company's development strategy quickly and effectively. We have confidence in our business fundamentals and market prospects in the United States. Therefore, we will continue to leverage our insight, expertise and industry relationships to identify attractive value-added investments in the United States. We believe that we are well positioned to deliver the next phase of growth and create long-term value for our investors."

07:46 EDT Biofrontera Inc. appoints Fred Leffler as CFO - Biofrontera announces the appointment of Fred Leffler as CFO, effective immediately. Most recently, Mr. Leffler was a Senior Manager at McKinsey & Company in Boston, having served in a similar capacity in their Washington, D.C. office earlier in his career.

07:40 EDT Marathon receive Federal Fisheries Act Authorization for Valentine Gold project - Marathon Gold announces that it has received full authorization pursuant to the federal Fisheries Act from Fisheries and Oceans Canada for the Valentine Gold Project in central Newfoundland. Receipt of this authorization allows Marathon to proceed with all site activities regulated by the Fisheries Act. Matt Manson, President and CEO, commented: "In our project update news release of October 12, 2022, we reported on a number of important provincial permits that we had received to allow our early works program to commence at Valentine, such as our Early Works Certificate of Approval, the Approval of the Early Works Development and Rehabilitation & Closure Plan, and the Approval of the Construction Environmental Protection Plan. This latest authorization under the Fisheries Act is a major permit under federal jurisdiction for the Project, and governs the important aspects of water management and the protection of fish and fish habitat. Its receipt is timely, and supports the scheduled site work currently underway. The early works mobilization at Valentine has gone well, and we are able to report good progress in each work area including temporary camp installation, grubbing and tree removal, pad construction, haul road development, and pre-strip mining for construction materials."

07:39 EDT Applied Materials appoints March to board of directors - Applied Materials (AMAT) announced the appointment of Kevin March to serve on its Board of Directors. March brings more than 30 years of finance and business operations expertise to Applied and will serve on the Board's Audit Committee. March is a retired, longtime executive of Texas Instruments Incorporated (TXN).

07:37 EDT Canacol Energy proposes share consolidation - The Corporation is also pleased to announce it will hold a Special Meeting of Shareholders on December 19, 2022. The Corporation has set the Record Date for the Special Meeting on November 18, 2022. The purpose of the Special Meeting is to seek authorization from the Corporation's shareholders to enable the Board of Directors to consider a consolidation of the Corporation's issued and outstanding common shares at a ratio of up to one post-consolidation share for every five pre-consolidation shares. The Corporation's Board will also present some routine amendments to its by-laws to match the recent amendments to the Business Corporations Act. Any authority of the Board to consolidate the shares is conditional upon the prior approval of the Corporation's shareholders and the Toronto Stock Exchange.

07:36 EDT Canacol Energy executes agreement with SETCO to construct gas pipeline - Canacol Energy announced that it has executed an agreement with the consortium Shanghai Engineering and Technology to construct a 289 kilometer long 22 inch diameter gas pipeline from the Jobo gas processing facility to the city of Medellin. SETCO is a Chinese based construction and pipe fabrication consortium with experience in building major gas pipelines in Asia and the Middle East. Under the terms of the agreement SETCO will be responsible for paying 100% of the cost of building the pipeline and will own, operate, and maintain the pipeline. The Corporation will not own or pay any part of the costs associated with the pipeline project, including its construction or operation. The Corporation's sole commitment under the agreement is limited to the execution of a transportation agreement whereby the Corporation will pay a fixed fee for a certain volume of gas over a certain period of time. The Corporation has already executed two 12 year take or pay gas sales contracts for a total volume of 75 million standard cubic feet per day going to Medellin through the pipeline and is currently negotiating additional long term take or pay gas sales contracts with customers in the interior to ensure that the new pipeline is filled to initial capacity of 100 MMscfpd. The pipeline is scheduled to enter operation in December 2024. The Corporation currently has a productive capacity of approximately 250 MMscfpd and anticipates increasing productive capacity to over 300 MMscfpd via the drilling of additional wells and the execution of additional infrastructure prior to the pipeline entering service.

07:34 EDT Genenta Science expects funds to be sufficient through the end of 2024 - As of June 30, 2022, the Company had EUR 34.7 million in cash and cash equivalents, as compared to EUR 37.2 million of cash and cash equivalents as of December 31, 2021. The Company expects these funds to be sufficient to fund operations through the end of 2024.

07:29 EDT Fury Gold Mines announces results from drill holes at Eau Claire project - Fury Gold Mines provides results for six core drill holes at the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. Drilling to date has tested five target areas at the Eau Claire deposit, significantly expanding the mineralized footprint. Drill holes 22EC-049 and 22EC-055 currently represent the western most drill holes and have extended gold mineralization a further 125 metres from the multiple high-grade zones of gold mineralization from drill hole 22EC-048 within the Hinge Target. Drill hole 22EC-055 intercepted eight zones of mineralization across a drilled width of 290m, including 4.0m of 5.75 g/t gold, 1.0m of 9.81 g/t gold and 3.0m of 1.93 g/t gold and drill hole 22EC-049 intercepted six zones of gold mineralization across 350m drilled width including 1.0m of 21.40 g/t gold and 4.50m of 1.09 g/t gold. The multiple stacked zones of gold mineralization encountered at the Hinge Target clearly demonstrate that the Eau Claire gold resource remains open to the west and has the potential to be expanded significantly with approximately a 25% increase to the mineralized footprint realized to date. "The Hinge Target continues to expand gold mineralization at the Eau Claire deposit which remains open for considerable expansion," commented Tim Clark, CEO of Fury. "We are looking forward to the remaining 14 holes from the Percival Target, the North Limb, the eastern extension, the Gap Zone, and the Hinge Target, which are pending assay and expected prior to year-end. Although assay times have been slow across the industry, the Company is in a strong financial position with over C$12.5m in our treasury, 50% of drill results pending from this summer's drill program, and extensive surface exploration results from across the Eau Claire land position."

07:25 EDT Prospect Capital announces results of cash tender offer for Senior Notes - Prospect Capital Corporation announced the results of its previously announced cash tender offer to purchase any and all of the outstanding notes. The Tender Offer was made pursuant to an Offer to Purchase dated October 17, 2022 which set forth the terms and conditions of the Tender Offer. As of the previously announced expiration time of 5:00 p.m., New York City time, on October 21, 2022, according to information provided by D.F. King & Co., Inc., the information and tender agent for the Tender Offer, a total of $1,508,000 aggregate principal amount of Notes had been validly tendered and not validly withdrawn in the Tender Offer. Withdrawal rights for the Notes expired at 5:00 p.m., New York City time, on October 21, 2022. The consideration to be paid for the Eligible Notes is $985.00 for each $1,000 principal amount of Eligible Notes, plus accrued and unpaid interest on the Eligible Notes, if any, from the applicable last interest payment date up to, but not including, the settlement date, which date is expected to be October 26, 2022.

07:20 EDT NFI Group reports quarter-end liquidity position over $470M - The company said, "NFI's quarter-end liquidity position was over $470 million, subject to a minimum liquidity covenant of $250 million. The Company anticipates its liquidity position will improve to over $500 million by the end of 2022 based on expected decreases in work-in-process inventory balances. NFI believes that through its action plan and in working with its banking, and federal and provincial government partners it can obtain temporary relief from the credit facility covenants that would otherwise become applicable on January 1, 2023. The Company continues to believe that, when combined with this relief, its cash position and capacity under its existing credit facilities, anticipated future cash flows and access to capital markets, will be sufficient to fund operations, meet financial obligations as they come due, and provide the funds necessary for dividends, capital expenditures, and other operational needs.:

07:19 EDT NFI Group reports backlog with over 4,150 equivalent units in firm orders - The company said, "NFI's backlog remained near record levels with more than 4,150 equivalent units in firm orders and over 4,350 equivalent option units at the end of the third quarter. The Company also had more than 1,350 units in bid awards pending, where a customer has selected NFI as the preferred provider, but formal contract documentation had not yet been received. These will drive future backlog growth. Overall market demand remains extremely strong in North America. The public transit active bid universe reached record levels of 10,107 equivalent units at the end of the quarter, an increase of 46.5% from the same time last year. This period also saw NFI submit its highest number of bids ever. In addition, there were 20,377 equivalent units in the five-year outlook4, providing long-term visibility for future orders. NFI expects this strong bid environment to continue into 2023 as customers utilize record investments by governments in public transit."

07:17 EDT Trevena announces OLINVYK poster presentation - Trevena announced that an abstract entitled, "A Randomized Double-blind Trial Comparing Oliceridine And Morphine On Ventilation In An Elderly Population" has been accepted for podium presentation in the "Best of Abstracts: Clinical Science" session at the ANESTHESIOLOGY 2022 Annual Meeting, being held October 21-25, 2022 in New Orleans, LA. The presentation was held Sunday, October 23. In the abstract, the authors highlighted the key findings of the randomized, double blind, crossover study. The study compared the analgesic and hypercapnic ventilatory responses of two doses of OLINVYK injection against two doses of IV morphine in a population of healthy elderly individuals. The study design is important given that older age and increased weight. The primary endpoint of the study was the ventilatory rate in response to inhaled carbon dioxide at an extrapolated end-tidal PCO2 of 55 mm Hg. The key findings from the study were: Overall. Both IV OLINVYK and IV morphine showed comparable levels of pain relief in response to anterior tibial electrical stimulation. IV OLINVYK, however, has a significantly reduced effect on respiratory function over time compared to IV morphine, as measured by the mean ventilatory profiles over time. Lower Dose. In contrast to lower dose IV morphine, the lower dose IV OLINVYK showed very little impact on respiratory function. Higher Dose. At the higher doses studied, less respiratory depression was seen over the 6-hour measurement period with IV OLINVYK. The peak level of respiratory depression was lower for IV OLINVYK compared to IV morphine, but this difference was not statistically significant. Respiratory function rapidly returned toward baseline from 3 hours onward among IV OLINVYK subjects compared to IV morphine. Consistent with Prior Data. These data replicate differential effects of IV OLINVYK versus IV morphine seen in an earlier study in a younger population. Comparing these results with the earlier study in younger subjects, these data confirm the known risk of older age as a clinical risk factor and demonstrate an increased sensitivity to opioid-induced respiratory depression among these elderly subjects. As with all opioids, serious, life-threatening, or fatal respiratory depression may occur in patients treated with OLINVYK as indicated in the boxed warning.

07:15 EDT LanzaTech, Woodside Energy announce strategic collaboration - Woodside Energy (WDS) and LanzaTech have announced a strategic collaboration with the signing of a Strategic Framework Agreement. Under the Strategic Framework Agreement Woodside will, in collaboration with LanzaTech and subject to a positive final investment decision, design, construct, own, maintain and operate pilot facilities relating to LanzaTech's technologies. The Strategic Framework Agreement also allows Woodside and LanzaTech to explore opportunities for the potential commercial scale-up of LanzaTech's technology, which seeks to convert greenhouse gas emissions into new products. In conjunction, Woodside has entered into a Subscription Agreement for a $50M investment in the common stock private investment in public equity of AMCI Acquisition Corp. II (AMCI), with which LanzaTech is expected to merge in a previously announced business combination transaction. The Strategic Framework Agreement and Woodside's PIPE investment are conditional on closing of the proposed business combination between LanzaTech and AMCI. Upon closing, the combined company is expected to trade on Nasdaq under the ticker symbol "LNZA".

07:13 EDT Enthusiast Gaming, NFL announce first NFL Family Game Night - The National Football League and Enthusiast Gaming announced the debut of NFL Family Game Night, a new three-part special series of NFL Tuesday Night Gaming designed as a platform for families and younger fans to play alongside their favorite players and gamers in a fun and entertaining format. With the support of key new media sponsorships from Nickelodeon and Universal Pictures, alongside existing sponsor Hulu + Live TV, NFL Family Game Night aims to deliver excitement for the entire family. NFL Family Game Night will debut on October 25 at 6:30 pm ET, inviting viewers to a Halloween-themed gaming night with content creators as well as NFL players and their children playing Fall Guys. The show will give viewers a peek into how these families and friends play together and the fun that ensues. The Halloween special will be the first of three NFL Family Game Nights planned throughout the inaugural NFL Tuesday Night Gaming season.

07:12 EDT Zentalis announces first ZN-c3 clinical development collaboration with Pfizer - Zentalis Pharmaceuticals (ZNTL) announced plans to initiate the first study of its collaboration with Pfizer (PFE) on Zentalis' product candidate ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells. The study is one component of Zentalis' strategic collaboration with Pfizer, which was previously announced along with Pfizer's $25 million equity investment in Zentalis. Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab-an FDA-approved standard of care known as the BEACON regimen-in patients with BRAF V600E-mutated metastatic colorectal cancer. Published studies indicate that up to 21% of mCRC patients have BRAF mutations and that the V600E mutation accounts for more than 95% of BRAF mutations. BRAF-mutated mCRC constitutes a more aggressive malignancy than non-BRAF-mutated mCRC, generally conferring worse survival outcomes. While the BEACON regimen established a new standard of care for patients with BRAF V600E-mutated mCRC-demonstrating statistically significant and clinically meaningful improvement in overall survival-all patients taking this regimen eventually progress, at which point they have limited additional treatment options. BRAF-mutated mCRC therefore continues to represent an area of significant unmet medical need. Preclinical evidence supports the rationale for combining inhibition of BRAF, Wee1 and EGFR. Wee1 inhibition has shown synergy with many targeted agents in mutationally driven cancers, and the addition of ZN-c3 to encorafenib and cetuximab enhanced anti-tumor activity in a cell-line-derived xenograft model. Zentalis anticipates initiating patient enrollment in the first quarter of 2023.

07:10 EDT Sutro Biopharma announces departure of Chief Medical Officer - Sutro Biopharma announced that Chief Medical Officer, Arturo Molina, M.D., M.S., F.A.C.P. will be leaving the company to pursue other opportunities, effective November 4, 2022. Sutro will continue its executive search for a new CMO. In the interim, Bill Newell CEO, with support from Sutro's senior clinical development team, will oversee all clinical activities and related functions.

07:09 EDT Gilat Satellite awarded over $10M to power IFC applications - Gilat Satellite Networks announced the receipt of more than $10M in orders for transceivers to power the IFC applications of a Tier-1 global aerospace system Integrator. Gilat's fully-owned US-based subsidiary, Wavestream, will provide its Ka-band AeroStream family of transceiver products to enable in-flight connectivity. "We are pleased to fulfill the burgeoning demand of our longtime trusted partner who, for years, has continued to rely on our Ka-band transceiver solution for in-flight connectivity," said Bob Huffman, Wavestream's General Manager and Gilat's Senior VP. "With these new orders, Wavestream is growing its lead in the IFC marketplace, now with over 3,000 units successfully operating on commercial and business aviation aircraft worldwide."

07:07 EDT Genius Sports announces long-term extension of bet365 partnership - Genius Sports has clinched a long-term extension of its official data partnership with bet365. Genius Sports will provide bet365 with its exclusive portfolio of official data rights including the Premier League, NFL, CFL, AHL, NASCAR and more. In addition, as the official data partner to the Mid-American Conference, Genius Sports will provide bet365 with the first and only official data feed for betting on NCAA sports. In another first, Genius Sports and bet365 will explore the implementation of Genius' unique suite of ground-breaking betting products powered by its Second Spectrum tracking and augmentation technology.

07:05 EDT Tricida announces VALOR-CKD trial did not meet primary endpoint - Tricida announced the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease, or CKD. The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease, or ESRD, or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate, or eGFR, also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 placebo-treated patients experienced a DD40 primary endpoint event, representing a veverimer to placebo hazard ratio of 0.99 over the 26.7 months median duration of treatment. The VALOR-CKD trial was an international, randomized, multicenter, double-blind, placebo-controlled trial of patients with CKD and metabolic acidosis. To qualify for enrollment in the study, patients were required to have two eGFR values, taken at least 2 weeks apart, in the range of 20 to 40 mL/min/1.73m2, that were not more than 20% different from each other and three serum bicarbonate values, each taken at least two weeks apart from the others and all three within a six-week period, in the range of 12 to 20 mEq/L. The entry criteria for the study also required that patients be on a stable, maximum-tolerated, labeled dose of an angiotensin converting enzyme, or ACE, inhibitor and/or angiotensin II receptor blocker, or ARB, for at least 4 weeks prior to and during the Screening Period. Both patients taking oral alkali supplements and those not taking them were eligible for enrollment; however, a patient's use and dose of oral alkali was not to be changed during the study and those taking oral alkali were required to be on a stable dose for at least two weeks prior to and during the screening period. There were no prohibited drugs. Eligible patients were enrolled into a single-blind active-treatment period of 4 to 8 weeks that was followed by a randomized withdrawal into a double-blind, randomized treatment period. Patients in Part A who experienced a greater than or equal to 4 mEq/L increase from baseline in serum bicarbonate and those whose serum bicarbonate increased into the normal range of greater than or equal to 22 mEq/L at Week 4 were randomized in a 1:1 ratio either to continue treatment with veverimer or to treatment with placebo for the double-blind, Part B, portion of the trial. Patients who did not achieve the required serum bicarbonate response to veverimer after 4 weeks in Part A continued to receive veverimer for an additional 4 weeks. After 8 weeks of veverimer treatment in Part A, those patients who experienced a greater than or equal to 4 mEq/L increase in serum bicarbonate and those whose serum bicarbonate increased into the normal range of greater than or equal to 22 mEq/L were randomized in a 1:1 ratio to either continued treatment with veverimer or to treatment with placebo in Part B. Those patients who did not achieve the desired serum bicarbonate response after 8 weeks in Part A discontinued treatment with veverimer and exited the study. In total, 2,198 patients received single-blind treatment with veverimer in Part A. Of these, 1,480 patients were randomized into Part B. The randomized patient population had a mean baseline eGFR of 29.2 mL/min/1.73m2 and a mean baseline serum bicarbonate of 17.5 mEq/L. The majority of patients randomized in the trial had one or more co-morbid conditions, such as hypertension, heart failure or diabetes. Approximately 12% of patients in the trial were taking oral alkali at baseline. The table below provides selected demographics and baseline characteristics of veverimer- and placebo-treated patients. Given the failure on the primary endpoint, our prespecified hierarchical analysis did not permit statistical testing of the secondary endpoints, however, the nominal p-values for all of these endpoints were non-significant.

07:03 EDT Scholastic to repurchase $75M of common stock via modified Dutch Auction - Scholastic announced that its Board of Directors has authorized the repurchase of up to $75M of the company's common stock through a modified "Dutch Auction" tender offer, at an anticipated cash purchase price per share of not less than $35.00 per share and not more than $40.00 per share, less any applicable withholding taxes and without interest. Scholastic intends to commence the Offer on Tuesday, October 25, with expiration of the Offer scheduled for 12:00 Midnight, at the end of the day, New York City time on Tuesday, November 22, unless the Offer is extended or earlier terminated. The purchase of common shares under the Offer will be funded entirely through the company's cash on hand.

07:02 EDT Arko Corp. announces agreement to acquire Pride Convenience for $230M - ARKO announced that GPM Investments, a wholly owned subsidiary of ARKO, has agreed to acquire Pride Convenience, which operates 31 convenience stores. This acquisition would expand ARKO's convenience store footprint into Massachusetts, making it the 34th state in which the Company will operate. "Our agreement to acquire Pride highlights ARKO's continued focus on creating long-term shareholder value by growing our core convenience store business," said Arie Kotler, ARKO's chairman, president and CEO. "We believe Pride stores are top-tier assets, with a focus on excellent customer service and a quality loyalty program, and we further believe that we can add value to these assets through our operational and merchandising abilities and scale. We look forward to welcoming Pride's employees to our Family of Community Brands and working together to enhance the business." The total purchase price for Pride is approximately $230M plus the value of inventory. At closing, ARKO intends to finance from its own sources approximately $28M of the cash consideration plus the value of inventory and other closing adjustments. The remaining approximately $202M is expected to be funded by Oak Street Real Estate Capital, a Division of Blue Owl Capital as part of the existing $1.15B agreement with the Company, according to which Oak Street is expected to acquire the real estate assets of Pride as part of the transaction. The Company would lease the real estate assets from Oak Street.

06:51 EDT Mallinckrodt receives approval to list on NYSE - Mallinckrodt announced that it has received approval to list its ordinary shares on NYSE American. Trading of the company's ordinary shares on NYSE American is expected to occur under the ticker symbol (MNK) beginning on October 27.

06:50 EDT Medtronic to separate Patient Monitoring, Respiratory Interventions businesses - Medtronic announced its intention to pursue a separation of the company's combined Patient Monitoring and Respiratory Interventions businesses, which are part of the company's Medical Surgical Portfolio. Following the separation of NewCo, Medtronic will have a more streamlined portfolio with focus on deploying capital into opportunities aligned with its long-term growth strategies; modestly faster organic revenue growth and an increased weighted average market growth rate and a balance sheet and continued commitment to its strategy of driving durable growth. NewCo is expected to be a partner for connected care solutions with brands and positions in patient monitoring and critical care: the Patient Monitoring technology portfolio includes Nellcor pulse oximetry, Microstream capnography, BIS brain monitoring, INVOS perfusion monitoring, and HealthCast connected care solutions. The Respiratory Interventions technology portfolio includes Puritan Bennett ventilators, Shiley airway portfolio, McGrath MAC video laryngoscopy, DAR breathing systems, as well as PAV+, NIV+ and IE Sync ventilation software solutions designed to improve workflow and care delivery. Patient Monitoring and Respiratory Interventions reside in the Respiratory, Gastrointestinal & Renal division within the Medtronic Medical Surgical Portfolio. In FY22, the combined business generated global revenue of approximately $2.2B. The combined business has a constant currency revenue growth profile and gross margin profile slightly below overall Medtronic and an operating margin profile slightly higher than overall Medtronic. The combined business has a global commercial footprint and a team of more than 8,000 employees worldwide. Medtronic plans to redeploy any net proceeds consistent with its stated capital allocation priorities. Medtronic does not expect this separation to impact its dividend policy. Medtronic expects the separation to be completed in the next 12 to 18 months subject to the satisfaction of closing conditions, including obtaining final approval from the Medtronic board of directors, receipt of tax opinions and receipt of other regulatory approvals. Medtronic plans to provide additional details on the potential transaction in due course. There can be no assurance regarding the ultimate timing or structure of the potential separation or that a separation will be completed at all, or if completed, what form the separation would take.

06:34 EDT Vaxcyte's pneumococcal vaccine candidate shows positive Phase 1/2 results - Vaxcyte announced 'positive' topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine or PCV, in healthy adults aged 18-64. In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to Prevnar 20 - PCV20 - for all doses studied. In the study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which the company intends to move forward into a Phase 3 program. At this dose, VAX-24 met the standard opsonophagocytic activity response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. These four incremental serotypes cover 10%-15% of strains causing invasive pneumococcal disease over the current standard-of-care in adults. Frequently reported local and systemic reactions were generally mild-to-moderate, resolving within several days of vaccination. No serious adverse events or new onset chronic illnesses were considered to be related to study vaccines. VAX-24 demonstrated robust OPA and immunoglobulin G immune responses for all 24 serotypes at all doses studied, each of which could advance into Phase 3.

06:18 EDT IHS Holding sets carbon emission reduction target of 50% by 2030 - IHS Holding announced its Carbon Reduction Roadmap. The Carbon Reduction Roadmap provides a comprehensive strategy for decreasing IHS Towers' emissions, including a goal to reduce the Scope 1 and Scope 2 kilowatt-hour emissions intensity of its tower portfolio by 50% by 2030, using 2021 emissions data as the baseline. Under Project Green, the next significant step of its Carbon Reduction Roadmap, the company expects to spend $214M in capex towards these efforts between 2022 and 2024, and to deliver annual Recurring Levered Free Cash Flow savings of $77M in 2025. This, in turn, is expected to generate an implied return on investment of 30%. As a result, IHS Towers is raising its 2022 capex guidance to $645M-685M from $545M-$585M, including $110M of the $214M spent for Project Green. Savings will be achieved by connecting more sites to the electricity grid and via the deployment and integration of battery storage and solar panel solutions. In scope for Project Green are IHS Towers' operations in Cameroon, Cote d'Ivoire, Kuwait, Nigeria, Rwanda, and Zambia where reliance on diesel generators has been traditionally greater.

06:04 EDT AstraZeneca's Imjudo+Imfinzi approved in U.S. for unresectable liver cancer - The company states: "AstraZeneca's Imjudo, or tremelimumab, in combination with Imfinzi, or durvalumab, has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer. The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody Imjudo 300mg added to the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks, is called the STRIDE regimen. The approval by the FDA was based on positive results from the HIMALAYA Phase III trial. In this trial, patients treated with the combination of Imjudo and Imfinzi experienced a 22% reduction in the risk of death versus sorafenib. Results were also published in the New England Journal of Medicine Evidence showing that an estimated 31% of patients treated with the combination were still alive after three years, with 20% of patients treated with sorafenib still alive at the same duration of follow-up.Reference Link

06:03 EDT Opthea appoints Timothy Morris as CFO - Opthea appointed Timothy Morris as CFO. Morris joins Opthea from Humanigen, where he served as COO/CFOsince his appointment in August 2020. Previously, Morris was CFO of Iovance Biotherapeutics . Prior to IOVA, Morris was CFO of AcelRx Pharmaceuticals, VIVUS Inc., and Questcor Pharmaceuticals Inc.

05:44 EDT Syncona to acquire Applied Genetic for 34c per share in cash - Applied Genetic announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona, will acquire AGTC, through a tender offer, for approximately $23.5M, or 34c per share, in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50M pursuant to contingent value rights, or CVRs. The board of directors of AGTC unanimously recommends that the shareholders of AGTC tender their shares in the tender offer once it is commenced. Under the terms of the definitive agreement, an indirect subsidiary of Syncona Limited will initiate a tender offer to acquire all outstanding shares of AGTC common stock. The upfront cash consideration in the transaction will consist of 34c per share of AGTC common stock. AGTC equity holders will also receive in the transaction, for each share of AGTC common stock, one non-tradeable CVR. The holders of the CVRs will be entitled to receive payments of up to an additional $50M in the aggregate upon the achievement of certain milestones related to transactions involving AGTC's assets and regulatory and commercial milestones related to AGTC's products. The 34c per share represents a premium of approximately 42% and the potential for up to $1.07 per share represents a premium of up to approximately 344% over AGTC's closing stock price on October 21. Under the terms of the definitive agreement, any shares not tendered in the tender offer will be acquired in a second-step merger at the same cash price as paid in the tender offer. The closing of the transaction is subject to customary closing conditions, including that the number of shares validly tendered and not validly withdrawn represents a majority of all shares of AGTC common stock then outstanding plus the aggregate number of shares issuable to holders of stock options and warrants in respect of which AGTC has received notices of exercise prior to the expiration of the tender offer. Upon the closing of the transaction, the shares of AGTC's common stock will no longer be listed on any public market. Subject to certain limited exceptions, the CVRs will be non-transferable. There can be no assurance that any contingent payments will be paid. Syncona plans to finance the upfront cash consideration in the transaction with cash on hand. The transaction was unanimously approved by AGTC's board of directors and is expected to close in the fourth quarter of 2022. All of the members of AGTC's board of directors and the executive officers of AGTC entered into a tender and support agreement with respect to all of the shares of AGTC common stock and/or stock options held by such persons, pursuant to which each such person agreed, among other things, to vote against other proposals to acquire AGTC and, subject to certain exceptions, to tender such person's AGTC shares pursuant to the tender offer.

05:35 EDT KKR, Mubadala Investment Company sign co-investing partnership in Asia Pacific - KKR and Mubadala Investment Company announced the signing of a strategic partnership that will see the two firms co-investing across performing private credit opportunities in the Asia Pacific region. The partnership aims to deploy at least $1B of long-term capital, providing bespoke credit solutions to companies and sponsors. Mubadala will deploy its capital alongside KKR's existing pools of capital, including the recently raised KKR Asia Credit Opportunities Fund, a $1.1B vehicle focused on performing, privately originated credit investments in the region.

05:29 EDT Credit Suisse to disgorge EUR 65.6M, pay EUR 57.4M in French legacy case - Credit Suisse announced that it has reached a settlement with the Parquet National Financier, or PNF, to resolve a legacy matter in relation to an investigation into historical cross-border private-banking services. The settlement provides for a public interest fine comprising a profit disgorgement of EUR 65.6M and the payment of an additional amount of EUR 57.4M. Further Credit Suisse will pay EUR 115M to the French State as damages. The settlement does not comprise a recognition of criminal liability. The bank is pleased to resolve this matter, which marks another important step in the proactive resolution of litigation and legacy issues.

05:18 EDT Gilead presents results from the BICSTaR study - Gilead announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV. The latest five-year data from two Phase 3 studies provide evidence of the long-term safety and efficacy profile of Biktarvy in those who switch from a dolutegravir-containing regimen. The data were presented at the 30th International Congress on Drug Therapy in HIV Infection. New real-world data was presented from the 24-month BICSTaR follow-up analysis, evaluating the effectiveness and safety of Biktarvy in clinical practice across nine countries. The analysis included follow-up during the COVID-19 pandemic and considered age, race, sex, adherence, and late diagnosis in the population group. Trial participants who initiated treatment with Biktarvy experienced high viral suppression. Overall, 97% of treatment-naive and 95% of treatment-experienced participants achieved viral suppression at 24 months. There were no reports of treatment-emergent resistance. Treatment discontinuations were low, and few people discontinued Biktarvy as a result of drug-related AEs, or DRAEs. The most commonly reported drug-related adverse events were weight change and depression. These data reinforce the safety and durability of Biktarvy for people with HIV with a high level of comorbidities. Additional data from Study 1489 and Study 1490 presented at the conference show Biktarvy to have high efficacy and sustained safety for people switching to the treatment, with a continued high barrier to resistance. These outcomes were reported in participants 96 weeks after switching to open-label Biktarvy following 144 weeks of blinded dolutegravir + 2 NRTIs. At Week 240, more than 99% of participants in both Study 1489 and Study 1490 achieved viral suppression. Additionally, at every visit through 240 weeks, the study showed that following the switch to Biktarvy, efficacy was greater than 96%, demonstrating that Biktarvy may provide sustained viral suppression for people with HIV, even after switching treatments. Biktarvy was generally well tolerated, with 0.4% (2/519) of switch participants in both studies experiencing an AE that led to drug discontinuation in the open-label extension period. There were no renal discontinuations. The most commonly reported adverse events during the open-label extension phase were diarrhea and weight change. On October 14, the FDA approved a label change for Biktarvy, updating the prescribing information to include efficacy data from 144 weeks and safety data from 240 weeks of clinical trial data in adults with HIV who were initiating therapy in Study 1489 and Study 1490.

05:10 EDT Alibaba kicks off 11.11 Global Shopping Festival - Alibaba kicked off the 14th edition of its 11.11 Global Shopping Festival, featuring more than 290,000 brands. This year, Alibaba will equip merchants with tools and solutions to grow their brand loyalty membership programs and unveil new products, among other initiatives. To date, more than 40 brands on Tmall have loyalty membership programs that surpassed 10M members and 600 brands have loyalty membership programs with over 1M members. 11.11 presale on Tmall will kick off at 8 pm Beijing time on October 24. Two check-out windows will follow - the first window will begin at 8pm on October 31 and end on November 3, while the second window will last from 8pm November 10 to November 11.